Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Paíno T, González-Méndez L, San-Segundo L, Corchete LA, Hernández-García S, Díaz-Tejedor A, Algarín EM, Mogollón P, Martín-Sánchez M, Gutiérrez NC, Mateos MV, Garayoa M, Ocio EM. Paíno T, et al. Cancers (Basel). 2020 Sep 24;12(10):2743. doi: 10.3390/cancers12102743. Cancers (Basel). 2020. PMID: 32987735 Free PMC article.
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Hernández-García S, San-Segundo L, González-Méndez L, Corchete LA, Misiewicz-Krzeminska I, Martín-Sánchez M, López-Iglesias AA, Algarín EM, Mogollón P, Díaz-Tejedor A, Paíno T, Tunquist B, Mateos MV, Gutiérrez NC, Díaz-Rodriguez E, Garayoa M, Ocio EM. Hernández-García S, et al. Haematologica. 2017 Dec;102(12):2113-2124. doi: 10.3324/haematol.2017.168666. Epub 2017 Aug 31. Haematologica. 2017. PMID: 28860344 Free PMC article.
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T, Garcia-Gomez A, González-Méndez L, San-Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho D, Ortiz-de-Solorzano C, Corchete LA, Gutiérrez NC, Maetos MV, Garayoa M, Ocio EM. Paíno T, et al. Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20. Clin Cancer Res. 2017. PMID: 27440267
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM. Algarín EM, et al. Haematologica. 2020 Mar;105(3):e116-e120. doi: 10.3324/haematol.2018.212308. Epub 2019 Jul 18. Haematologica. 2020. PMID: 31320555 Free PMC article. No abstract available.
Filanesib for the treatment of multiple myeloma.
Algarín EM, Hernández-García S, Garayoa M, Ocio EM. Algarín EM, et al. Expert Opin Investig Drugs. 2020 Jan;29(1):5-14. doi: 10.1080/13543784.2020.1703179. Epub 2019 Dec 12. Expert Opin Investig Drugs. 2020. PMID: 31815551 Review.
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.
López-Iglesias AA, González-Méndez L, San-Segundo L, Herrero AB, Hernández-García S, Martín-Sánchez M, Gutiérrez NC, Paíno T, Avilés P, Mateos MV, San-Miguel JF, Garayoa M, Ocio EM. López-Iglesias AA, et al. Haematologica. 2017 Jan;102(1):168-175. doi: 10.3324/haematol.2016.146076. Epub 2016 Aug 18. Haematologica. 2017. PMID: 27540138 Free PMC article.
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM. López-Iglesias AA, et al. J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y. J Hematol Oncol. 2017. PMID: 28633670 Free PMC article.
Antitumoral effect of Ocoxin on acute myeloid leukemia.
Díaz-Rodríguez E, Hernández-García S, Sanz E, Pandiella A. Díaz-Rodríguez E, et al. Oncotarget. 2016 Feb 2;7(5):6231-42. doi: 10.18632/oncotarget.6862. Oncotarget. 2016. PMID: 26756220 Free PMC article.
The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential.
Iglesias JM, Leis O, Pérez Ruiz E, Gumuzio Barrie J, Garcia-Garcia F, Aduriz A, Beloqui I, Hernandez-Garcia S, Lopez-Mato MP, Dopazo J, Pandiella A, Menendez JA, Martin AG. Iglesias JM, et al. Front Oncol. 2014 Nov 4;4:308. doi: 10.3389/fonc.2014.00308. eCollection 2014. Front Oncol. 2014. PMID: 25414831 Free PMC article.
54 results